Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herpes Virus C5252 Injection in Patients With Intracranial Tumor
NCT07243340Phase 2Recruiting
- Sponsor
- ImmVira
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in malignant glioma, sponsored by ImmVira. Primary endpoints: Incidence of adverse events at 30 days, Maximum Tolerated Dose / Recommended Phase 2 Dose at 4 weeks and 2 more. Started Apr 2026; status: recruiting.
02
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT07243340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07243340.